Mechanical Circulatory Support: LVAD in Heart Failure
Advanced heart failure is a serious medical condition with a poor prognosis despite optimal medical management. Heart transplantation remains the gold standard for the treatment of advanced heart failure, but it is severely limited by chronic donor shortage. In such scenario, contemporary continuous flow LVAD is emerging as an alternative to transplant in very selected patients. A thorough evaluation of the right ventricular function is mandatory before implantation because the device will support only the left ventricle. Survival is 80 and 70% at 1 and 2 years after LVAD implantation, respectively. During support, patients experience a significant improvement in functional status and quality of life, even if it is still inferior when compared to heart transplantation. LVAD also allows the treatment of severe reversible pulmonary hypertension, decreasing the risk of the transplantation. Most frequent complications observed during support are bleeding and infection. LVAD thrombosis, albeit much less frequent, is a life-threatening event that can lead to pump stop and even death. Treatment options for thrombosis are thrombolytic therapy, LVAD replacement, and urgent transplantation.
- 2.Lund LH, Edwards LB, Dipchand AI, Goldfarb S, Kucheryavaya AY, Levvey BJ, et al.; International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: thirty-third adult heart transplantation Report-2016; focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant. 2016;35(10):1158–69.Google Scholar
- 3.Eurotransplant International Foundation. Annual Report 2015. https://www.eurotransplant.org/cms/mediaobject.php?file=AR_ET_20153.pdf.
- 4.Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al.; Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.Google Scholar
- 8.Peura JL, Colvin-Adams M, Francis GS, Grady KL, Hoffman TM, Jessup M, et al.; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Recommendations for the use of mechanical circulatory support: device strategies and patient selection: a scientific statement from the American Heart Association. Circulation. 2012;126(22):2648–67.Google Scholar
- 13.Starling RC, Estep JD, Horstmanshof DA, Milano CA, Stehlik J, Shah KB, et al.; ROADMAP Study Investigators. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: the ROADMAP Study 2-Year Results. JACC Heart Fail. 2017. pii:S2213-1779(17)30164-6.Google Scholar
- 16.Arnold SV, Jones PG, Allen LA, Cohen DJ, Fendler TJ, Holtz JE, et al. Frequency of poor outcome (death or poor quality of life) after left ventricular assist device for destination therapy: results from the INTERMACS Registry. Circ Heart Fail. 2016;9(8). pii: e002800.Google Scholar
- 17.Grady KL, Wissman S, Naftel DC, Myers S, Gelijins A, Moskowitz A, et al. Age and gender differences and factors related to change in health-related quality of life from before to 6 months after left ventricular assist device implantation: Findings from Interagency Registry for Mechanically Assisted Circulatory Support. J Heart Lung Transplant. 2016;35(6):777–88.CrossRefGoogle Scholar
- 24.Pae WE, Connell JM, Adelowo A, Boehmer JP, Korfer R, El-Banayosy A, et al.; Clinical Utility Baseline Study (CUBS) Group. Does total implantability reduce infection with the use of a left ventricular assist device? The LionHeart experience in Europe. J Heart Lung Transplant. 2007;26(3):219–29.CrossRefGoogle Scholar